Compound Profile: Tadalista 40 Fortune Health Care
Tadalista 40 is a tadalafil citrate formulation manufactured by Fortune Health Care specifically designed for laboratory research applications. This compound represents a standardised preparation of the phosphodiesterase-5 (PDE5) inhibitor tadalafil, enabling researchers at Stroid UK Shop to investigate the molecular mechanisms underlying PDE5 enzyme inhibition. Tadalafil citrate serves as a valuable research tool for examining cyclic guanosine monophosphate (cGMP) pathways and vascular smooth muscle cell responses in controlled laboratory environments. The compound’s chemical properties make it particularly suitable for studies examining endothelial function, nitric oxide signalling cascades, and smooth muscle physiology in various tissue models.
Laboratory Research Applications
Research scientists utilise Tadalista 40 to examine PDE5 enzyme kinetics and investigate the downstream effects of cGMP pathway modulation in cell culture systems. The compound facilitates studies into vascular biology, including research on smooth muscle contractility and endothelial-dependent relaxation mechanisms. Investigators studying cardiovascular physiology employ this formulation to analyse nitric oxide-mediated signalling pathways and their role in vascular homeostasis. Additionally, researchers exploring tadalafil citrate compounds utilise these preparations to examine pharmacokinetic properties and tissue-specific responses. Studies investigating pulmonary vascular biology also benefit from standardised tadalafil preparations for examining smooth muscle responses and pressure dynamics in experimental models.
Technical Specifications
| Parameter | Value |
|---|---|
| Active Compound | Tadalafil Citrate |
| Manufacturer | Fortune Health Care |
| Product Code | EU11720 |
| Molecular Formula | C₂₂H₁₉N₃O₄·C₆H₈O₇ |
| CAS Number | 171596-29-5 (citrate salt) |
| Storage Conditions | Room temperature, dry environment |
Researchers examining other molecular targets may also investigate selective androgen receptor modulators or peptide compounds to understand complementary signalling pathways in comprehensive research programmes.
Research Compliance Statement
Tadalista 40 is supplied exclusively for legitimate laboratory research purposes and in-vitro scientific investigations. This product is not intended for human consumption, therapeutic application, or any form of in-vivo administration. All research activities must comply with institutional guidelines and applicable regulations governing laboratory research compounds. Researchers must possess appropriate qualifications and work within accredited laboratory facilities when handling this material. The compound should be stored according to manufacturer specifications and disposed of following proper laboratory waste management protocols.
